Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1033620160430040207
Clinical and Experimental Reproductive Medicine
2016 Volume.43 No. 4 p.207 ~ p.214
Anti-Mullerian hormone as a predictor of polycystic ovary syndrome treated with clomiphene citrate
Hestiantoro Andon

Negoro Yuwono Sri
Afrita Yohana
Wiweko Budi
Sumapradja Kanadi
Natadisastra Muharam
Abstract
Objective: This study aimed to determine the threshold of anti-Mullerian hormone (AMH) as predictor of follicular growth failure in polycystic ovary syndrome (PCOS) patients treated with clomiphene citrate (CC).

Methods: Fifty female subjects with PCOS were recruited and divided into two groups based on successful and unsuccessful follicular growth. Related variables such as age, infertility duration, cigarette smoking, use of Moslem hijab, sunlight exposure, fiber intake, body mass index, waist circumference, AMH level, 25-hydroxy vitamin D level, and growth of dominant follicles were obtained, assessed, and statistically analyzed.

Results: The AMH levels of patients with successful follicular growth were significantly lower (p=0.001) than those with unsuccessful follicular growth (6.10¡¾3.52 vs. 10.43¡¾4.78 ng/mL). A higher volume of fiber intake was also observed in the successful follicular growth group compared to unsuccessful follicular growth group (p=0.001). Our study found the probability of successful follicle growth was a function of AMH level and the amount of fiber intake, expressed as Y=?2.35+(?0.312¡¿AMH level)+(0.464¡¿fiber intake) (area under the curve, 0.88; 95% confidence interval, 0.79?0.98; p<0.001).

Conclusion: The optimal threshold of AMH level in predicting the failure of follicle growth in patients with PCOS treated with CC was 8.58 ng/mL.
KEYWORD
Anti-Mullerian hormone, Clomiphene citrate, Ovarian follicle, Polycystic ovary syndrome
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø